Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Amgen Stories

2013-07-11 08:29:01

Editor Note: For more information about this release, please scroll to bottom. LONDON, July 11, 2013 /PRNewswire/ -- On Wednesday, July 10, 2013, shares in biotechnology companies ended mostly higher even as the broader market ended on a mixed note. The major movers in the industry included Amgen Inc. (NASDAQ: AMGN), PDL BioPharma Inc. (NASDAQ: PDLI), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), and BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX). All these companies are tracked...

2013-07-09 12:27:36

Over 50,000 Participants Join Together to Fight Nation's Leading Cause of Disability ATLANTA, July 9, 2013 /PRNewswire/ -- The Arthritis Foundation announced today that the nationwide 2013 Arthritis Walk is projected to raise more than $10 million in hopes of finding a cure and ending arthritis pain for the 50 million people who suffer from arthritis. The annual event takes places in 137 cities across the country through November. (Logo:...

2013-07-09 08:29:41

Amgen Obtains US Rights to Novel EU-Approved Cardiovascular Therapy; Servier Receives Option for Omecamtiv Mecarbil in Europe THOUSAND OAKS, Calif., and SURESNES, France, July 9, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Servier today announced a new collaboration agreement leveraging each company's commitment to cardiovascular disease. Under the terms of the agreement, Amgen has obtained commercial rights in the U.S. to Servier's novel oral drug, approved in the EU as...

2013-07-03 23:20:46

Neurological Wellness Center physicians report the alleviation of depression is a predictable outcome of perispinal Enbrel treatment of Alzheimer's disease. (PRWEB) July 03, 2013 A survey performed by the Department of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine and published in the Journal Biological Psychiatry finds: "Depression is one of the most frequent comorbidities of Alzheimer's disease, affecting up to 50% of AD patients."...

2013-07-01 08:28:05

Nearly half a million dollars given to physicians working to cure psoriatic diseases PORTLAND, Ore., July 1, 2013 /PRNewswire-USNewswire/ -- Twelve residents and medical students each received a one-year, $40,000 National Psoriasis Foundation fellowship to study psoriasis and psoriatic arthritis. The National Psoriasis Foundation Amgen Medical Dermatology Fellowships aims to increase the number of scientists studying and treating psoriatic diseases by encouraging promising doctors to...

2013-06-19 23:23:43

Newly published research by the prestigious Dana Foundation elucidates the operational mechanisms enabling the restoration of mental faculties. NWC physicians applaud the Dana Foundation's contribution to understanding the role neuro-inflammation plays in the pathogenesis of Alzheimer's disease. (PRWEB) June 19, 2013 Pharmaceutical history is replete with examples of drugs being utilized to treat conditions with little or no understanding why they work, with a clear understanding of the...

2013-06-19 16:26:37

Award Demonstrates Amgen's Commitment to the Next Generation of Innovators and the Teachers who Inspire Them THOUSAND OAKS, Calif., June 19, 2013 /PRNewswire/ -- Amgen is pleased to announce the nine science teachers in the United States, Canada and Puerto Rico who are this year's recipients of the Amgen Award for Science Teaching Excellence (AASTE). Now in its 21st year, the award recognizes extraordinary teachers at the kindergarten through 12th grade level who have an outstanding...

2013-06-13 16:26:36

XGEVA Becomes First FDA-Approved Treatment for This Rare Disease THOUSAND OAKS, Calif., June 13, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA(®) (denosumab) for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone (GCTB) that is unresectable or where surgical resection is likely to result in severe morbidity. XGEVA was approved following a...

2013-06-12 23:26:51

Neurological Wellness Center physician's group seeks sponsors for pilot study to evaluate the efficacy of perispinally administered Stelara as an Alzheimer's treatment. (PRWEB) June 12, 2013 Currently clinical trials are ongoing in the U.S., Nicaragua and U.K. to evaluate the efficacy of the FDA approved psoriasis drug Enbrel as an Alzheimer's treatment.* Similar clinical trials are needed to evaluate the efficacy of the FDA approved psoriasis drug Stelara as an Alzheimer's treatment. Both...

2013-06-12 08:29:39

Study Meets Primary Endpoint of Progression-Free Survival THOUSAND OAKS, Calif., June 12, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Phase 3 TRINOVA-1 trial evaluating trebananib plus paclitaxel versus placebo plus paclitaxel in recurrent ovarian cancer met its primary endpoint of progression-free survival (PFS). A statistically significant difference was observed in PFS with a 34 percent reduction in the risk of disease progression or death (HR = 0.66, 95...